Absci completes first milestone in AstraZeneca oncology collaboration; AI-designed antibodies delivered

Absci Corp

Absci delivered AI-designed antibody sequences to AstraZeneca, fulfilling first milestone under December 2023 collaboration.
AstraZeneca elected to advance sequences into AI-lead optimization phase.
Collaboration combines Absci's Integrated Drug Creation platform with AstraZeneca's oncology expertise.
Goal: accelerate discovery of a potential new cancer treatment candidate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.